Radiation myelopathy …

Neuro-Oncology

Updated 10.17.2023
Released 12.27.1996
Expires For CME 10.17.2026

Radiation myelopathy

Authors: Sean P Pitroda MD, Muzamil Arshad MD

See Contributor Disclosures

Editor: Deric M Park MD FACP

Radiation myelopathy

In This Article

Quick Link

Introduction

Overview

Radiation myelopathy is a relatively rare, but potentially devastating, complication of therapeutic irradiation. As systemic treatments improve and patients live longer with cancer, the incidence of spinal metastases (cord, leptomeningeal, dural, epidural) will continue to increase and necessitate the application of palliative radiation, stereotactic body radiotherapy (SBRT), and re-irradiation to the spine. Therefore, the incidence of radiation myelopathy will likely increase, and recognition of the subacute and chronic progressive forms of radiation myelopathy will become critical to distinguish from recurrent tumor and permit early intervention. The authors summarize the clinical features, pathophysiology, and management issues for patients with radiation myelopathy.

Key points

	• Radiation myelopathy is a rare complication of modern therapeutic radiation.
	• The generally accepted dose and fractionation parameters predicting the risk of radiation myelopathy may not necessarily apply to patients who receive a second course of radiation, concurrent radiation plus chemotherapy, or spinal stereotactic radiosurgery.
	• Most patients with chronic progressive radiation myelopathy are permanently neurologically disabled; there is no proven effective therapy.

Historical note and terminology

Spinal cord injury following therapeutic radiation was first recognized in the mid-1940s, shortly after the introduction of megavoltage radiotherapy (04; 33). The term "radiation myelopathy" encompasses at least three distinct clinicopathologic entities: (1) a common, but mild subacute (transient) myelopathy, (2) a less common, but catastrophic chronic progressive (delayed) myelopathy, and (3) an unusual selective lower motor neuron syndrome. Therapeutic radiation has also been implicated in spinal cord hemorrhage, the induction of spinal cord neoplasms, and development of vascular malformations.

Clinical manifestations

Presentation and course

Subacute (transient) myelopathy. The most common form of radiation-induced spinal cord injury is subacute (transient) myelopathy, which can occur following craniospinal axis irradiation for primary CNS tumors, or after "incidental" radiation of the cord for treatment of lymphoma or extraneural tumors of the head, neck, or thorax. The incidence of subacute radiation myelopathy varies, ranging from 4% of patients in a large series of patients irradiated for head and neck cancer (57) to upwards of 15% among patients receiving mantle field radiotherapy for Hodgkin lymphoma (103). The syndrome is more frequent among patients receiving a total spinal cord dose of greater than 5000 cGy, larger daily radiation dose fractions, or a larger volume spinal cord irradiated (20; 57).

Subacute myelopathy occurs after a latent period of 1 to 30 months following the completion of radiation, with the peak onset at 4 to 6 months (103; 32; 57). The syndrome consists of paresthesias or "electric shock" sensations radiating down the spine (Lhermitte phenomenon), which frequently extend down the limbs. These symptoms are often precipitated or worsened by neck flexion or physical exertion. Patients rarely report other symptoms and almost never show any objective signs of extremity weakness or sphincter dysfunction. The syndrome is thought to be due to temporary demyelination of the posterior columns of the spinal cord and is not thought to be a precursor of chronic progressive myelopathy. MR scans are unrevealing, although increased spinal cord metabolic activity with positive PET imaging has been reported (19). The syndrome typically resolves gradually over 1 to 9 months.

Chronic progressive (delayed) myelopathy. Delayed injury to the spinal cord typically presents as a chronic progressive myelopathy. Although rare, chronic progressive myelopathy is an ominous late complication of radiation. Unlike transient myelopathy, it is usually irreversible, and there is no treatment with established benefit. Chronic progressive radiation myelopathy usually presents with numbness or dysesthesias in the legs, followed by weakness and sphincter dysfunction, with an upper level of cord dysfunction ascending to lie within the irradiated area (66). Pain is usually not a prominent complaint. A Brown-Sequard hemicord pattern is fairly common early in the course (40).

The incidence of chronic progressive myelopathy appears to be bimodal, most commonly occurring after latent intervals of 12 to 14 months and 24 to 28 months, with a rough inverse correlation between radiation dose and the latent interval (88). Exceptional patients have latent intervals as short as 3 months or as long as 10 years after radiation (40; 66; 32). To date, most of the reported cases of chronic progressive myelopathy following stereotactic radiosurgery occurred within 12 months after treatment (84). In most patients, the neurologic deficits progress over several weeks to months and often plateau but rarely improve spontaneously.

Lower motor neuron syndrome. A rare syndrome of selective damage to lower motor neurons occurs following spinal radiation for medulloblastoma (80), lymphoma (25), or germ cell tumors (33; 37; 21). Patients develop roughly symmetric bilateral leg weakness beginning 4 to 14 months after completion of radiation. Examination shows muscle atrophy, fasciculations, normal or decreased muscle stretch reflexes, flexor plantar responses, and no sensory or sphincter involvement. Weakness is confined to the legs, even in patients who received irradiation to the entire spine (80), with little or no sensory loss or change in bladder and bowel function (21). The syndrome usually progresses slowly over several months, and then stabilizes, but does not improve. Motor and sensory nerve conduction velocities are normal, and electromyographic evidence of diffuse denervation, including lumbar paraspinal muscles, has been demonstrated (37). In some published cases, spine MR scans are normal (15), but others have reported gadolinium enhancement of the cauda equina (05). Lumbosacral anterior horn cells were initially believed to be the primary site of damage in these patients, but it is now thought to be more consistent with a radiculopathy rather than a neuronopathy (05).

Subacute radiation myelopathy, chronic progressive radiation myelopathy, and lower motor neuron syndrome are summarized in Table 1.

Table 1. Types of Radiation Myelopathy

Types of radiation myelopathy	Time to onset post-radiation	Presenting symptoms	Imaging findings	Pathologic findings	Natural course of disease progression
Subacute (transient) myelopathy	1 to 30 months (median 5 months)	Paresthesias or Lhermitte phenomenon	Normal MR, PET avidity of spinal cord	Reversible demyelination of the posterior columns	Gradual resolution over 1 to 9 months
Chronic progressive (delayed) myelopathy	3 months to 10 years (median 20 months)	Ascending paresthesias, dysesthesias, or sensory loss in one or both lower extremities, followed by weakness and sphincter dysfunction	MR shows widening of the spinal cord, hyperintensity on T2 and fluid-attenuated inversion recovery (FLAIR) sequences	Damage to small blood vessels and direct injury to glia and myelin	Progresses over weeks to months then stabilizes
Lower motor neuron syndrome	4 to 14 months	Bilateral weakness confirmed to lower extremities	Gadolinium enhancement of the roots of the cauda equina	Vasculopathy of the proximal spinal roots, with preservation of lower motor neuronal cell bodies and spinal cord architecture	Progresses over several months then stabilizes

Prognosis and complications

For patients with subacute myelopathy, symptoms tend to gradually resolve without medical intervention over 1 to 9 months. For patients with chronic progressive radiation myelopathy, the neurologic deficits progress over weeks to months in a steady or (less commonly) stepwise fashion, leading to paraplegia or quadriplegia in more than half of patients. A few patients show slow and partial spontaneous recovery (49), but it is rare for ambulation to be regained once it is lost. Patients with severe neurologic deficits frequently have shortened survival due to pneumonia, pulmonary embolus, or other medical complications (91).

In the handful of reported cases of radiation myelopathy following spinal radiosurgery, the latent interval to onset of neurologic symptoms was shorter, and the likelihood of subsequent neurologic improvement was higher, than is generally seen in myelopathy after standard fractionated external beam radiation (29). It is possible that the pathophysiology of spinal cord injury may differ according to the type of radiation administered. For lower motor neuron syndrome, bilateral lower extremity weakness progresses slowly over several months and then stabilizes, with most patients remaining ambulatory.

Clinical vignette

This is a fictitious clinical vignette of a patient developing chronic progressive radiation myelopathy.

A 70-year-old man with prostate adenocarcinoma developed diffuse back pain without other neurologic symptoms and was found to have multiple vertebral metastases without epidural tumor extension. He received radiotherapy from the T1 through T8 vertebral bodies to a total dose of 3500 cGy given in daily fractions of 250 cGy. His pain improved, and he felt well until 7 months after completion of radiotherapy when he developed painless, progressive, bilateral leg weakness and numbness. He denied change in bowel or bladder function. Examination 6 weeks after onset of symptoms showed the following: 3+/5 to 4/5 weakness in both legs, worse on the left; hyperreflexia of the left leg and a left Babinski sign; a sensory level to pinprick on the right trunk at T10 (without sacral sparing); impaired temperature sensation in the same distribution on the right; and decreased vibration and position sense on the left leg and foot. MR scan showed abnormal signal on T2-weighted images in the spinal cord from C7 through T8, without cord widening. There was patchy linear enhancement in the spinal cord from T4 through T7. The patient was given dexamethasone 16 mg per day and noted subjective improvement in gait stability, without any other change in symptoms or signs.

MRI of spinal cord, T4-T7 (MRI)

Contrast-enhanced MR scan in the sagittal plane (A) and axial plane (B) (T5-T6 interspace) showing patchy areas of abnormal enhancement within the spinal cord from T4 through T7. The spinal cord is not widened. There is also abnor...

Biological basis

Etiology and pathogenesis

As no therapeutically effective radiotherapy regimen is known that carries zero risk of spinal cord injury, careful treatment planning and administration of radiotherapy with particular regard for spinal cord tolerance parameters is necessary to reduce the risk of radiation myelopathy. The risk of developing chronic progressive radiation myelopathy is largely, but not entirely, dependent on the total dose and size of the dose fraction of radiation. There are several formulas for calculating a "dose equivalent" that allow comparison of the radiobiological effect and risk of toxicity among different fractionation schedules. These formulas contain a correction factor to account for the fact that the spinal cord is more sensitive to the size of the daily dose fraction than are many other tissues. The most commonly used model for describing the response of the spinal cord and other "late reacting" tissues to once-daily radiation is the linear quadratic formula (23; 104; 50; 71). Radiosensitivity of tissue in this model is described by the alpha-beta ratio, with lower values corresponding to lower radiosensitivity. The practical clinical usefulness of such formulas has been questioned (99) as these formulas do not accurately predict the risk of radiation myelopathy following hyperfractionated (more than once daily) radiation schedules (104; 42; 71; 87), nor do they accurately predict spinal cord tolerance to stereotactic radiosurgery (46; 13). Furthermore, radiation myelopathy has occurred after "safe" radiation doses in combination with high-dose or intensive chemotherapy regimens, such as those used for hematopoietic stem cell transplantation (36; 10; 92; 17; 93; 27), as well as following immunotherapy administration after radiation for non-small cell lung cancer (08; 48). The risk of delayed radiation myelopathy as a function of radiation dose needs to be considered separately for patients who: (1) are previously untreated and receive conventional fractionated external-beam radiation to the entire cross-section of the spinal cord, (2) receive a second course of fractionated external-beam radiation to the entire cross-section of the spinal cord, or (3) receive stereotactic radiosurgery with high-dose exposure to a partial cross-section of the spinal cord (46).

Conventionally fractionated radiotherapy in previously untreated patients. For patients receiving a single course of fractionated radiation, the dose-risk relationship differs between the cervical and thoracic spinal cord due to differences in the radiosensitivity. Reirradiation doses are typically expressed in equivalent dose in 2 Gy fractions (EQD2), which accounts for the total dose, the dose per fraction, and the radiosensitivity of the tissue expressed using alpha-beta ratios. When radiation is given in once-daily fractions and dosing regimens are analyzed according to the equivalent dose at 200 Gy daily fractions, the risk of delayed cervical myelopathy is approximately 0.03% after 45 Gy, 0.2% at 50 Gy, 5% at 60 Gy, and 50% at 69 Gy (53; 52; 18; 41; 01; 87; 46). The thoracic spinal cord is generally less sensitive to radiation injury than the cervical cord; the risk of chronic progressive myelopathy increases to 30% to 40% at doses greater than 65 Gy but without a steep dose-response curve at higher doses as is the case for cervical myelopathy (01; 87). Unexplained differences in individual sensitivity to radiation result in the occurrence of chronic progressive radiation myelopathy in an extremely small percentage of patients who receive a "safe" radiation regimen (107; 105). Additionally, in the cervical spinal cord, the risk of chronic progressive radiation myelopathy increases with increasing lengths of spinal cord irradiated (01). For the thoracic spinal cord, published analyses do not indicate a definite relationship between irradiated rostral-caudal spinal cord volume and the risk of chronic progressive myelopathy (52; 42; 71; 99; 01; 87; 46).

Conventionally fractionated radiotherapy in previously treated patients. Some patients with primary head and neck tumors, lung cancer, or vertebral metastases receive second courses of radiation, exposing the spinal cord to total doses up to 9000 cGy or more (102; 85; 77; 35). These patients have an increased but not easily quantified risk of chronic progressive radiation myelopathy. Evaluating the risk of radiation myelopathy requires consideration of the radiation dose regimen, spinal cord volume, irradiated region for each course of radiation, and the time interval between radiation courses. Experimental animal studies and clinical data suggest that the spinal cord recovers from "occult" radiation injury over approximately 2 to 3 years, so palliative reirradiation may be given without a terribly high risk of radiation myelopathy during a patient’s lifetime (60; 61; 70; 46). Updated results from a bi-institutional study with an expanded cohort suggests that patients treated to higher cumulative doses or at higher risk of myelopathy based on prior risk scores remain free of myelopathy; however, the median follow-up was only 12 months (16).

Alternative models for estimating the retreatment radiation tolerance of the spinal cord at different points in time following an initial dose of radiation have been investigated (43; 101). These models utilize primate data (02) to fit parameters as well as incorporate other clinical and preclinical observations, such as the observation that in rodent models the recovery of the spinal cord after initial radiation dose begins around 70 days later (97; 100). The authors provide detailed sample calculations for how to utilize their models clinically, including an example in which a patient who initially received 40 Gy in 2 Gy fractions to the spinal cord could receive reirradiation 2 years later with approximately 36 Gy in 3 Gy fractions and have the same risk of developing radiation myelopathy (0.12%) with retreatment as with the initial treatment.

Stereotactic body radiotherapy (SBRT). Single-dose or fractionated stereotactic radiosurgery is increasingly used to treat metastatic vertebral tumors (with or without epidural extension) (82) or primary tumors such as meningioma, schwannoma, or hemangioblastoma (13). Many patients with spinal metastases treated with stereotactic radiosurgery have previously received standard fractionated radiation to the same area. The radiobiology of this high-dose focused radiation differs from that of conventional fractionated external beam radiotherapy, both in terms of the tumor effect and on the risk of injury to the adjacent spinal cord. The steep dose fall-off within and near the spinal radiosurgery target volume means that there is heterogeneous radiation exposure to the spinal cord and a possibility that a small volume of spinal cord receives a high radiation dose. Determining the risk of radiation myelopathy after spinal radiosurgery, therefore, needs to take this "partial volume effect" into account (78; 82; 13). The reported risk of radiation myelopathy after stereotactic radiosurgery for spinal metastases is generally less than 1% (29; 46; 84), though it is somewhat higher in some reports (26). Variability in re-irradiation doses at the time of SBRT can complicate interpretation of radiation myelopathy rates. Ito and colleagues reported myelopathy rates in 123 patients (133 lesions), with 40% of lesions having a Bilsky grade of 2 to 3 (38). Patients underwent re-irradiation with a uniform dose of 24 Gy in two fractions using PRV cord constraint of less than 12.2 Gy or less than 11 Gy if patients’ prior course of radiotherapy was more than 50 Gy EQD2. At a median follow-up of 12 months (range 1 to 57 months) four patients developed myelopathy (3%) ranging from 5 to 37 months after SBRT. There are reports of chronic progressive radiation myelopathy occurring in patients who receive stereotactic radiosurgery after prior conventional fractionated radiation (83). Chronic progressive radiation myelopathy occurred in 1 of 17 patients with spinal cord hemangioblastoma treated with single-dose or hypofractionated stereotactic radiosurgery (13). Overall, the rates of myelopathy in both the de novo and re-irradiation setting with SBRT are low, and risk of myelopathy must be weighed against complications from tumor progression. Adherence to dose constraints and technical aspects of SBRT is critical (65).

There are emerging data to estimate the risk of delayed radiation myelopathy based on the spinal cord dose and volume parameters for single-fraction and fractionated stereotactic radiosurgery (84; 34). There is possibly an influence of prior fractionated radiation therapy, or concurrent chemotherapy, or both on the development of radiation myelopathy in these patients. Although this is not clearly known, reported factors associated with a lower risk of radiation myelopathy for reirradiation patients include minimum time interval to reirradiation of 5 months or more and cumulative thecal sac equivalent dose in 2 Gy fractions with an alpha/beta of 2 Dmax ≤ 70 Gy (81). For spine SBRT in patients without a history of prior spinal radiotherapy, consensus guidelines suggest limiting single fraction maximum point dose (Dmax) to 1000 to 1400 Gy (with 1000 cGy being delivered to less than 10% of the spinal cord), or 5 fraction Dmax of 2500-3000 cGy (73). Per the Hypofractionation Treatment Effects in the Clinic (HyTEC) report, for de novo SBRT delivered in 1 to 5 fractions the following spinal cord Dmax are estimated to be associated with a 1% to 5% risk of radiation myelopathy: 12.4 to 14.0 Gy in 1 fraction, 17.0 Gy in 2 fractions, 20.3 Gy in 3 fractions, 23.0 Gy in 4 fractions, and 25.3 Gy in 5 fractions (81). Corresponding estimated risk calculations for developing radiation myelopathy based on the Stanford spine SBRT series have been developed to assist predicting the risk of developing radiation myelopathy (34). For reirradiation SBRT in 1 to 5 fractions, lower risk of myelopathy is reported for cumulative thecal sac dose of less than 70 Gy in EQD2; SBRT thecal sac Dmax less than 25 Gy, thecal sac SBRT EQD2 Dmax to cumulative EQD2 Dmax ratio of less than 0.5, and a minimum time interval to reirradiation of longer than 5 months (81). With improvements in systemic therapies and increases in survival, there is concern that rates of radiation myelopathy may increase. In a prospectively maintained database, Zeng and colleagues evaluated the risk of late toxicity for patients receiving spine SBRT whose survival was more than 3 years (106). Among those who lived more than 3 years, only 10% had prior radiotherapy. The majority (96%) of patients received 20 to 28 Gy in two fractions. The 5-year plexopathy rate was 5.1%. These data are reassuring and highlight the importance of proper technique when delivering ablative radiotherapy. Though beyond the scope of this article, it should be noted that MRI or CT myelogram are critical for accurate delineation of the spinal cord and thecal sac, which is absolutely necessary for delivery of SBRT along with image guidance during treatment.

Pathologic changes in radiation myelopathy. Subacute radiation myelopathy is generally believed to be caused by reversible demyelination of the posterior columns. This is supported by animal studies, but because of the self-limited nature of subacute radiation myelopathy, no published human pathology exists. From evidence of autopsied patients and from animal studies, chronic progressive radiation myelopathy appears to be the result of a combination of damage to small blood vessels and direct injury to glia, myelin, and inflammatory reactions (89; 62; 63; 39). The histopathology of chronic progressive radiation myelopathy is somewhat variable, both between patients and in different areas of the spinal cord in the same patient (40; 06; 66). White matter is characteristically more severely affected than gray matter, with a predilection for the posterior and superficial lateral columns. Coalescing foci of demyelination and axonal degeneration in these areas are accompanied by Wallerian degeneration above and below the necrotic zones. In the most severe cases, areas of total coagulative necrosis occur. In cases where gray matter is involved, the neurons may show central chromatolysis, but are often remarkably preserved. A spectrum of severity occurs with changes in small blood vessels, including fibrinoid necrosis of the vessel walls, hyaline thickening and obliteration of lumens, telangiectasias, extravasation of hyaline material, and occasional perivascular lymphocytic cuffing. In some autopsied cases, the severity of vascular changes appears to be mild compared to the degree of demyelination and parenchymal necrosis. The nerve roots and anterior or posterior spinal arteries are not involved, even adjacent to areas of extensive cord necrosis. Some evidence exists stipulating that direct damage to glia and myelin predominates in patients with relatively short latent intervals, whereas patients with longer latent intervals show more prominent vascular changes, although a considerable variability and overlap among patients does occur (74; 90; 49). The pathologic changes associated with lower motor neuron syndrome suggest a radiation-induced vasculopathy of the proximal spinal roots, with preservation of lower motor neuronal cell bodies and spinal cord architecture.

Differential diagnosis

The differential diagnosis of radiation myelopathy includes recurrent or metastatic tumor, new primary spinal neoplasm occurrence (76; 59), symptomatic spinal cord cavernous malformations from prior craniospinal axis irradiation (51; 58), neurotoxicity of chemotherapy, and remote paraneoplastic effects of cancer on the spinal cord. The distinguishing features between the presentations of these disorders are briefly described below. In addition, non-treatment-related and non-cancer-related autoimmune, infectious, or toxic-metabolic etiologies for spinal cord injury can be considered. The history should help guide the likelihood of these etiologies.

Recurrent, metastatic, or new primary spinal neoplasm occurrence. Epidural spinal metastases produce early and prominent pain in upwards of 90% of patients and should easily be diagnosed by MR imaging. A more difficult differential diagnosis is radiation myelopathy versus intramedullary spinal cord metastasis, although most patients with intramedullary metastases have a primary lung carcinoma (44; 14; 95). Patients present with a combination of pain, weakness, sensory loss, and urinary incontinence, with up to 50% of patients presenting with Brown-Sequard syndrome. Any level of the cord may be affected. Among patients irradiated for primary spinal cord gliomas, no clinical or neuroimaging features reliably distinguish chronic progressive radiation myelopathy from recurrent tumor (105; 67).

Neurotoxicity of chemotherapy. Acute myelopathy is a rare, but well-recognized complication of intrathecal administration of methotrexate or cytarabine in patients with leukemia, lymphoma, or a variety of solid tumors. Myelopathy may occur even with palliative doses of radiotherapy in the setting of intrathecal chemotherapy (24). The latency is extremely variable, from within a few hours of the first intrathecal chemotherapy injection to several months after completion of a course of several injections. No clear relationship to the cumulative dose of intrathecal chemotherapy exists (75). The syndrome can occur with or without concomitant systemic chemotherapy or cord irradiation (72). Patients typically develop a rapidly ascending flaccid paraparesis with a sensory level and bowel or bladder involvement, occasionally with early back and leg pain. MR scans in a few reported patients show focal cord swelling, decreased signal intensity on T1-weighted images, or patchy cord enhancement.

Paraneoplastic disorders. There are several ways in which paraneoplastic disorders can affect the spinal cord. Patients with paraneoplastic encephalomyelitis associated with small cell lung carcinoma, thymoma, or other neoplasms may present with a predominant subacute myelopathy syndrome (22). Some of these patients have myelopathy with rigidity, myeloradiculopathy, or myelopathy plus optic neuritis (11; 68; 45). Spine MRI scans may show localized or more longitudinally extensive T2-weighted signal abnormalities (22). Associated antineuronal autoantibodies include anti-Hu, anti-CV2, and anti-amphiphysin.

A syndrome of muscle rigidity and spasms that clinically resembles “stiff-person syndrome” is associated with a variety of neoplasms, including small cell lung carcinoma and breast carcinoma. Rigidity is probably caused by multifocal encephalomyelitis affecting the spinal cord, or brainstem, or both. Patients develop progressive aching and rigidity of the axial and proximal limb musculature, usually asymmetric at onset. There are superimposed painful and sometimes violent spasms, either occurring spontaneously or triggered by voluntary movement, passive movement, or sensory stimuli. There is clinical overlap with a syndrome of "encephalomyelitis with rigidity and myoclonus." Some patients have antibodies against the synaptic vesicle-associated protein amphiphysin (68), or against glycine receptors (54).

Paraneoplastic necrotizing myelopathy is a rare complication of a variety of carcinomas, lymphomas, and leukemias, without a clear preponderance of any specific tumor type (64). Several cases have occurred after apparent cure of the associated tumor. Patients present with subacute painless bilateral weakness, sensory symptoms, and sphincter dysfunction. Physical examination may initially demonstrate a Brown-Sequard syndrome, but more commonly reveals a specific level of transverse spinal cord dysfunction. Nearly all patients suffer rapid deterioration of function and a progressively ascending level of flaccid paralysis and numbness.

Some patients with small cell lung carcinoma and multifocal paraneoplastic encephalomyelitis develop focal or diffuse lower motor neuron weakness and atrophy. In these patients, autopsy demonstrates patchy loss of anterior horn cells and variable inflammatory infiltrates within the spinal cord (12). As with other manifestations of paraneoplastic encephalomyelitis, the motor neuron involvement in these patients tends to progress independently of the status of the underlying neoplasm.

An unusual syndrome of "subacute motor neuronopathy" occurs in patients with Hodgkin disease, non-Hodgkin lymphomas, and thymoma (86). Patients develop subacute progressive weakness, often asymmetric or patchy and predominantly involving the legs, without pain or significant sensory loss. Examination reveals a pure lower motor neuron picture with moderate to severe weakness, fasciculations, atrophy, and diminished deep tendon reflexes. CSF is acellular, but occasionally shows mildly elevated protein. The syndrome may occur prior to the discovery of a neoplasm, as well as after attainment of complete remission. The neurologic deficits generally worsen over weeks to months independent of the course of the malignancy, but usually spontaneously stabilize or improve (sometimes dramatically) after a period of months to years. Autopsy shows patchy degeneration and loss of anterior horn cells, occasional inflammatory infiltrates, secondary thinning of ventral nerve roots, and widespread patchy segmental demyelination of spinal roots and brachial and lumbosacral plexuses.

References

01: Adamus-Gorka M, Brahme A, Mavroidis P, Lind BK. Variation in radiation sensitivity and repair kinetics in different parts of the spinal cord. Acta Oncol 2008;47(5):928-36. PMID 18568487
02: Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001;50(4):1013-20. PMID 11429229
03: Angibaud G, Ducasse JL, Baille G, Clanet M. Potential value of hyperbaric oxygenation in the treatment of post-radiation myelopathies. Rev Neurol 1995;151:661-6. PMID 8745630
04: Boden G. Radiation myelitis of the cervical spinal cord. Br J Radiol 1948;21:464-9. PMID 18878308
05: Bowen J, Gregory R, Squier M, Donaghy M. The post-irradiation lower motor neuron syndrome neuronopathy or radiculopathy? Brain 1996;119(Pt 5):1429-39. PMID 8931568
06: Burns RJ, Jones AN, Robertson JS. Pathology of radiation myelopathy. J Neurol Neurosurg Psychiatry 1972;35:888-98. PMID 4647860
07: Calabro F, Jinkins JR. MRI of radiation myelitis: a report of a case treated with hyperbaric oxygen. Eur Radiol 2000;10:1079-84. PMID 11003402
08: Carausu M, Beddok A, Langer A, et al. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature. J Immunother Cancer 2019;7(1):317. PMID 31753021
09: Chamberlain MC, Eaton KD, Fink J. Radiation-induced myelopathy: treatment with bevacizumab. Arch Neurol 2011;68:1608. PMID 22159063
10: Chao MW, Wirth A, Ryan G, MacManus M, Liew KH. Radiation myelopathy following transplantation and radiotherapy for non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1998;41:1057-61. PMID 9719115
11: Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003;54:38-50. PMID 12838519
12: Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine 1992;71:59-72. PMID 1312211
13: Daly ME, Luxton G, Choi CY, et al. Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery. Int J Rad Oncol Biol Phys 2012;82:2025-32. PMID 21531516
14: Dam-Hieu P, Seizeur R, Mineo JF, et al. Retrospective study of 19 patients with intramedullary spinal cord metastases. Clin Neurol Neurosurg 2009;111:10-7. PMID 18930587
15: De Carolis P, Montagna P, Cipulli M, et al. Isolated lower motoneuron involvement following radiotherapy. J Neurol Neurosurg Psychiatry 1986;49:718-9. PMID 3734833
16: Doi H, Tamari K, Oh RJ, Nieder C. New clinical data on human spinal cord re-irradiation tolerance. Strahlenther Onkol 2021;197(6):463-73. PMID 33950265
17: Dormann S, Duffner U, Martini C, Bohm N, Korinthenberg R, Niemeyer C. Brief report: chronic myelopathy after combined chemo-radiotherapy in a patient with relapsed mediastinal B-cell lymphoma. Med Pediatr Oncol 2002;38(6):442-4. PMID 11984808
18: Emami B, Lyman J, Brown A, et al. Tolerance of normal tissues to therapeutic irradiation. Int J Rad Oncol Biol Phys 1991;21:109-22. PMID 2032882
19: Esik O, Csere T, Stefanits K, et al. Increased metabolic activity in the spinal cord of patients with long-standing Lhermitte's sign. Strahlenther Onkol 2003;179(10):690. PMID 14566477
20: Fein DA, Marcus RB, Parsons JT, Mendenhall WM, Million RR. Lhermitte's sign: incidence and treatment variables influencing risk after irradiation of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1993;27:1029-33. PMID 8262823
21: Feistner H, Weissenborn K, Münte TF, Heinze HJ, Malin JP. Post-irradiation lesions of the caudal roots. Acta Neurol Scand 1989;80(4):277-81. PMID 2554633
22: Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011;76:2089-95. PMID 21670438
23: Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989;62:679-94. PMID 2670032
24: Fukuda Y, Takashashi S, Nakamura M, et al. Radiation myelopathy caused by palliative radiotherapy and intrathecal methotrexate. Case Rep Oncol 2022;15(2):674-81. PMID 35949907
25: Gallego J, Delgado G, Tunon T, Villanueva JA. Delayed postirradiation lower motor neuron syndrome. Ann Neurol 1986;19:308-9. PMID 3963778
26: Garg AK, Shiu AS, Yang J, et al. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer 2012;118:5069-77. PMID 22511344
27: Gatcombe H, Lawson J, Phuphanich S, Crocker I. Treatment related myelitis in Hodgkin's lymphoma following stem cell transplant, chemotherapy and radiation. J Neuro-Oncol 2006;79:293-8. PMID 16617406
28: Ge L, Arul K, Mesfin A. Spinal cord injury from spinal tumors: prevalence, management, and outcomes. World Neurosurg 2019;122:e1551-6. PMID 30471447
29: Gibbs IC, Patil C, Gerszten PC, Adler JR Jr, Burton SA. Delayed radiation-induced myelopathy after spinal radiosurgery. Neurosurgery 2009;64(2):A67-72. PMID 19165076
30: Glantz MJ, Burger PC, Friedman AH, et al. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994;44:2020-7. PMID 7969953
31: Godwin-Austen RB, Howell DA, Worthington B. Observations on radiation myelopathy. Brain 1975;98:557-68. PMID 1218367
32: Goldwein JW. Radiation myelopathy: a review. Med Pediatr Oncol 1987;15:89-95. PMID 3295502
33: Greenfield MM, Stark FM. Post-irradiation neuropathy. Am J Roentgenol 1948;60:617-22. PMID 18895006
34: Grimm J, Sahgal A, Soltys SG, et al. Estimated risk level of unified stereotactic body radiation therapy dose tolerance limits for spinal cord. Semin Radiat Oncol 2016;26:165-71. PMID 27000514
35: Grosu AL, Andratschke N, Nieder C, Molls M. Retreatment of the spinal cord with palliative radiotherapy. Int J Rad Oncol Biol Phys 2002;52:1288-92. PMID 11955741
36: Higgins RV, Myers VT, Hall JB. Radiation myelopathy after chemotherapy and radiation therapy for fallopian tube carcinoma. Gynecol Oncol 1997;64:285-7. PMID 9038279
37: Horowitz SL, Stewart JD. Lower motor neuron syndrome following radiotherapy. Can J Neurol Sci 1983;10:56-8. PMID 6839230
38: Ito K, Ogawa H, Nakajima Y. Efficacy and toxicity of re-irradiation spine stereotactic body radiotherapy with respect to irradiation dose history. Jpn J Clin Oncol 2021;51(2):264-70. PMID 33020807
39: Jacob J, Feuvret L, Simon JM, et al. Neurological side effects of radiation therapy. Neurol Sci 2022;43(4):2362-74. PMID 35149927
40: Jellinger K, Sturm KW. Delayed radiation myelopathy in man: report of twelve necropsy cases. J Neurol Sci 1971;14:389-408. PMID 5125754
41: Jeremic B, Djuric L, Mijatovic L. Incidence of radiation myelitis of the cervical spinal cord at doses of 5500 cGy or greater. Cancer 1991;68:2138-41. PMID 1913452
42: Jeremic B, Shibamoto Y, Milicic B, Acimovic L, Milisavljevic S. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:343-6. PMID 9457819
43: Jones B, Hopewell JW. Alternative models for estimating the radiotherapy retreatment dose for the spinal cord. Int J Radiat Biol 2014;90:731-41. PMID 24894515
44: Kalayci M, Cagavi F, Gul S, et al. Intramedullary spinal cord metastases: diagnosis and treatment. Acta Neurochir 2004;146:1347-54. PMID 15526223
45: Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with CRMP-5 immunoglobulin G. Ann Neurol 2008;63:531-4. PMID 18306241
46: Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Rad Oncol Biol Phys 2010;76(Suppl):S42-9. PMID 20171517
47: Koehler PJ, Verbiest H, Jager J, Vecht CJ. Delayed radiation myelopathy: serial MR-imaging and pathology. Clin Neurol Neurosurg 1996;98:197-201. PMID 8836601
48: Kubo K, Wadasaki K, Yamane H, Doi M. Radiation myelitis after durvalumab administration following chemoradiotherapy for locally advanced non-small cell lung cancer: an illustrative case report and review of the literature. Int Cancer Conf J 2019;8(3):118-21. PMID 31218187
49: Lengyel Z, Reko G, Majtenyi K, et al. Autopsy verifies demyelination and lack of vascular damage in partially reversible radiation myelopathy. Spinal Cord 2003;41(10):577-85. PMID 14504618
50: Macbeth FR, Wheldon TE, Girling DJ, et al. Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clin Oncol 1996;8:176-81. PMID 8814372
51: Maraire JN, Abdulrauf SI, Berger S, Knisel YJ, Awad IA. De novo development of a cavernous malformation of the spinal cord following spinal axis radiation. Case report. J Neurosurg 1999;90(4 Suppl):234-8. PMID 10199254
52: Marcus RB, Million RR. The incidence of myelitis after irradiation of the cervical spinal cord. Int J Radiat Biol Oncol Phys 1990;19:3-8. PMID 2380091
53: McCunniff AJ, Liang MJ. Radiation tolerance of the cervical spinal cord. Int J Radiat Oncol Biol Phys 1989;16:675-8. PMID 2921166
54: McKeon A, Martinez E, Lancaster E, et al. Glycine receptor autoimmune spectrum with stiff-man syndrome phenotype. JAMA Neurol 2013;70:44-50. PMID 23090334
55: Melki PS, Halimi P, Wibault P, Masnou P, Doyon D. MRI in chronic progressive radiation myelopathy. J Comput Assist Tomogr 1994;18:1-6. PMID 8282856
56: Michikawa M, Wada Y, Sano M, et al. Radiation myelopathy: significance of gadolinium enhancement in the diagnosis. Neuroradiology 1991;33:286-9. PMID 1881553
57: Mul VE, de Jong JM, Murrer LH, et al. Lhermitte sign and myelopathy after irradiation of the cervical spinal cord in radiotherapy treatment of head and neck cancer. Strahlenther Onkol 2012;188:71-6. PMID 22194023
58: Narayan P, Barrow DL. Intramedullary spinal cavernous malformation following spinal irradiation. J Neurosurg (Spine 1) 2003;98:68-72. PMID 12546391
59: Ng C, Fairhall J, Stening W, Smee R. Spinal cord glioblastoma induced by radiation after treatment for Hodgkin disease. J Neurosurg Spine 2007;6:364-7. PMID 17436928
60: Nieder C, Grosu AL, Andratschke NH, Molls M. Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients. Int J Rad Oncol Biol Phys 2005;61:851-5. PMID 15708265
61: Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Rad Oncol Biol Phys 2006;66:1446-9. PMID 17084560
62: Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 2004a;10(10):3342-53. PMID 15161688
63: Nordal RA, Wong CS. Intercellular adhesion molecule-1 and blood-spinal cord barrier disruption in central nervous system radiation injury. J Neuropathol Exp Neurol 2004b;63(5):474-83. PMID 15198126
64: Ojeda VJ. Necrotizing myelopathy associated with malignancy: a clinicopathologic study of two cases and literature review. Cancer 1984;53:1115-23. PMID 6362838
65: Ong WL, Wong S, Soliman H, et al. Radiation myelopathy following stereotactic body radiation therapy for spine metastases. J Neurooncol 2022;159(1):23-31. PMID 35737172
66: Palmer JJ. Radiation myelopathy. Brain 1972;95:109-22. PMID 5023080
67: Phuphanich S, Jacobs M, Murtagh FR, Gonzalvo A. MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Surg Neurol 1996;45:362-5. PMID 8607087
68: Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96-107. PMID 15984030
69: Psimaras D, Tafani C, Ducray F, et al. Bevacizumab in late-onset radiation-induced myelopathy. Neurology 2016;86(5):454-7. PMID 26740673
70: Rades D, Rudat V, Veninga T, et al. Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. Cancer 2008;113:1090-6. PMID 18642349
71: Rampling R, Symonds P. Radiation myelopathy. Curr Opin Neurol 1998;11:627-32. PMID 9870128
72: Raney B, Tefft M, Heyn R, et al. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer 1992;69:1498-506. PMID 1540886
73: Redmond KJ, Lo SS, Soltys SG, et al. Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey. J Neurosurg Spine 2017;26(3):299-306. PMID 27834628
74: Reinhold HS, Van Putten WL, Hopewell JW, Van der Kogel AJ. The latent period in clinical radiation myelopathy. Int J Radiat Oncol Biol Phys 1984;10:2385-7. PMID 6511535
75: Resar LM, Phillips PC, Kastan MB, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993;71:117-23. PMID 8416707
76: Riffaud L, Bernard M, Lespimple T, Morandi X. Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review. J Neuro-Oncol 2006;76:207-11. PMID 16158216
77: Ryu S, Gorty S, Kazee AM, et al. "Full dose" reirradiation of human cervical spinal cord. Am J Clin Oncol 2000;23:29-31. PMID 10683070
78: Ryu S, Jin J, Jin R, et al. Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer 2007;109:628-36. PMID 17167762
79: Saager M, Hahn EW, Peschke P, et al. Ramipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation. J Radiat Res 2020;61(5):791-8. PMID 32657322
80: Sadowsky CH, Sachs E, Ochoa J. Postradiation motor neuron syndrome. Arch Neurol 1976;33:786-7. PMID 985158
81: Sahgal A, Chang JH, Ma L, et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Rad Oncol Biol Phys 2021;110(1):124-36. PMID 31606528
82: Sahgal A, Larson DA, Chang EL. Stereotactic body radiosurgery for spinal metastases: a critical review. Int J Rad Oncol Biol Phys 2008;71:652-65. PMID 18514775
83: Sahgal A, Ma L, Weinberg V, et al. Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Rad Oncol Biol Phys 2012;82(1):107-16. PMID 20951503
84: Sahgal A, Weinberg V, Ma L, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 2013;85(2):341-7. PMID 22713832
85: Schiff D, O'Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology 1996;47:906-12. PMID 8857717
86: Schold SC, Cho ES, Somasundaram M, Posner JB. Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol 1979;5:271-87. PMID 443760
87: Schultheiss TE. The radiation dose-response of the human spinal cord. Int J Radiat Oncol Biol Phys 2008;71(5):1455-9. PMID 18243570
88: Schultheiss TE, Higgins EM, El-Mahdi AM. The latent period in clinical radiation myelopathy. Int J Radiat Oncol Biol Phys 1984;10:1109-15. PMID 6378847
89: Schultheiss TE, Stephens LC, Jiang GL, Ang KK, Peters LJ. Radiation myelopathy in primates treated with conventional fractionation. Int J Radiat Oncol Biol Phys 1990;19:935-40. PMID 2211262
90: Schultheiss TE, Stephens LC, Maor MH. Analysis of the histopathology of radiation myelopathy. Int J Radiat Oncol Biol Phys 1988;14:27-32. PMID 3275603
91: Schultheiss TE, Stephens LC, Peters LJ. Survival in radiation myelopathy. Int J Radiat Oncol Biol Phys 1986;12:1765-9. PMID 3759528
92: Schwartz DL, Schechter GP, Seltzer S, Chauncey TR. Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy for non-Hodgkin's lymphoma. Bone Marrow Transplant 2000;26(12):1355-9. PMID 11223979
93: Seddon BM, Cassoni AM, Galloway MJ, et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma. Clin Oncol (Royal Coll Radiol) 2005;17:385-90. PMID 16097572
94: Shah N, Ranjan S. Successful treatment of quadriparesis from radiation myelopathy with bevacizumab in a patient with metastatic breast cancer. BMJ Case Rep 2022;15(2):e246470. PMID 35110282
95: Sung WS, Sung MJ, Chan JH, et al. Intramedullary spinal cord metastases: a 20-year institutional experience with a comprehensive literature review. World Neurosurg 2013;79(3-4):576-84. PMID 22484768
96: Uchida K, Nakajima H, Takamura T, et al. Neurological improvement associated with resolution of irradiation-induced myelopathy: serial magnetic resonance imaging and positron emission tomography findings. J Neuroimaging 2009;19(3):274-6. PMID 18681929
97: van der Kogel AJ, Sissingh HA, Zoetelief J. Effect of X rays and neutrons on repair and regeneration in the rat spinal cord. Int J Radiat Oncol Biol Phys 1982;8(12):2095-7. PMID 7161162
98: Wang PY, Shen WC, Jan JS. MR imaging in radiation myelopathy. AJNR Am J Neuroradiol 1992;13:1049-55. PMID 1636513
99: Werner-Wasik M, Yu X, Marks LB, Schultheiss TE. Normal-tissue toxicities of thoracic radiation therapy: esophagus, lung, and spinal cord as organs at risk. Hematol Oncol Clin North Am 2004;18(1):131-60, x-xi. PMID 15005286
100: Wong CS, Hao Y. Long-term recovery kinetics of radiation damage in rat spinal cord. Int J Radiat Oncol Biol Phys 1997;37(1):171-9. PMID 9054893
101: Woolley TE, Belmonte-Beitia J, Calvo GF, Hopewell JW, Gaffney EA, Jones B. Changes in the retreatment radiation tolerance of the spinal cord with time after the initial treatment. Int J Radiat Biol 2018;94(6):515-531. PMID 29620431
102: Wong CS, Van Dyk J, Milosevic M, Laperriere NJ. Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys 1994;30:575-81. PMID 7928488
103: Word JA, Kalokhe UP, Aron BS, Elson HR. Transient radiation myelopathy (Lhermitte's sign) in patients with Hodgkin's disease treated by mantle irradiation. Int J Radiat Oncol Biol Phys 1980;6:1731-3. PMID 7239993
104: Yaes RJ, Patel P, Maruyama Y. On using the linear quadratic formula in daily clinical practice. Int J Radiat Oncol Biol Phys 1991;20:1353-62. PMID 2045309
105: Yasui T, Yaura H, Komiyama M, et al. Significance of gadolinium-enhanced magnetic resonance imaging in differentiating spinal cord radiation myelopathy from tumor. J Neurosurg 1992;77:628-31. PMID 1527624
106: Zeng KL, Sahgal A, Tseng CL, et al. Prognostic factors associated with surviving less than 3 months vs greater than 3 years specific to spine stereotactic body radiotherapy and late adverse events. Neurosurgery 2021;88(5):971-9. PMID 33475723
107: Zweig G, Russell EJ. Radiation myelopathy of the cervical spinal cord: MR findings. AJNR Am J Neuroradiol 1990;11:1188-90. PMID 2124055

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Sean P Pitroda MD

Dr. Pitroda of The University of Chicago Medicine has no relevant financial relationships to disclose.
See Profile
Muzamil Arshad MD

Dr. Arshad of the University of Chicago has no relevant financial relationships to disclose.
See Profile

Editor

Deric M Park MD FACP

Dr. Park of the University of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

Timothy L Sita MD PhD
Tim J Kruser MD
Rimas V Lukas MD
Edward J Dropcho MD (original author)

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Radiation myelopathy

Associated Disorders

Lymphoma

Differential Diagnosis

recurrent or metastatic tumor
neurotoxicity of chemotherapy
remote effects of cancer on spinal cord
epidural spinal metastasis
intramedullary spinal cord metastasis
- spinal cord astrocytoma
- cavernous malformations
- paraneoplastic disorders
- paraneoplastic encephalomyelitis
- syndrome of muscle rigidity and spasm resembling stiff person syndrome
- acute myelopathy
- intrathecal methotrexate
- intrathecal cytarabine
- carcinoma
- lymphoma
- leukemia
- small cell lung carcinoma
- multifocal paraneoplastic encephalomyelitis
- Hodgkin disease
- non-Hodgkin lymphoma
- thymoma

Also Relevant

Cancer pain
Chemotherapy: neurologic complications
Intramedullary spinal cord metastatic tumors
Metastatic epidural spinal cord compression
Radiation: CNS complications
- Radiation plexopathy
- Spinal astrocytoma

Clinical Categories

Neuro-Oncology

Radiation myelopathy …

Radiation myelopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Types of Radiation Myelopathy

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Tumors of the skull base

Ganglioglioma

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

NTRK-fused tumors of the central nervous system

Anti-LGI1 encephalitis

Brain metastases

Radiation myelopathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. Types of Radiation Myelopathy

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Tumors of the skull base

Ganglioglioma

Paraneoplastic syndromes

Overview of neuropathology updates for infiltrating gliomas

NTRK-fused tumors of the central nervous system

Anti-LGI1 encephalitis

Brain metastases

This is an article preview.
Start a Free Account
to access the full version.